Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early‐onset Alzheimer's disease

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early‐onset Alzheimer's disease

Abstract Introduction People with Down syndrome (DS) are at high risk for Alzheimer's disease (AD). Defects in monoamine neurotransmitter systems are implicated in DS and AD but have not been comprehensively studied in DS. Methods Noradrenaline, adrenaline, and their metabolite 3‐methoxy‐4‐hydr...

Full description

Bibliographic Details
Main Authors: Alain D. Dekker, Yannick Vermeiren, Maria Carmona‐Iragui, Bessy Benejam, Laura Videla, Ellen Gelpi, Tony Aerts, Debby Van Dam, Susana Fernández, Alberto Lleó, Sebastian Videla, Anne Sieben, Jean‐Jacques Martin, Netherlands Brain Bank, Rafael Blesa, Juan Fortea, Peter P. De Deyn
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:
Alzheimer's disease
Cerebrospinal fluid
Dementia
Dopamine
Down syndrome
Monoamines
Online Access:https://doi.org/10.1016/j.dadm.2017.11.001

Internet

https://doi.org/10.1016/j.dadm.2017.11.001

Similar Items